Velo3D Expands Team in Europe to Support Growing Demand for Industrial Metal Additive Manufacturing
As global demand for top-quality 3D-printed industrial parts continues to grow, California-based Velo3D, Inc., a leader in advanced additive manufacturing (AM) for high-value metal parts, has announced the appointment of two new Europe-based senior executives.
Managing Director, Dr. Jose Greses, will be based between Germany and Spain while Sales Director, Xavier Fruh, will be located in France. They join Jon Porter, who was appointed earlier this year as European Business Development Director based in the U.K.
Dr. Greses holds a Ph.D. in laser welding from the University of Cambridge (U.K.) and a M.Sc. in Marine Technology from Cranfield University (U.K.). He has worked for a number of leading European manufacturing companies in laser welding and 3D-printing—most recently with GF Machining Solutions and, prior to that, for 14 years with German AM company EOS.
"Our goal is to help industries solve their engineering challenges by delivering unprecedented design freedom, part repeatability and quality in metal 3D printing," says Dr. Greses. "We're here to provide the European markets with a seamless transition to Velo3D's end-to-end manufacturing solution including its advanced support-free technology."
Xavier Fruh has a Master's degree in electrical engineering from ESIGELEC Rouen and an M.B.A. from the Strasbourg School of Management, both in France. He has years of experience in the welding industry and most recently did business development around Europe for four years with AddUp, a French group specializing in AM technology.
"I am passionate about innovation and technology," Fruh says. "I'm keen to support our customers in overcoming the limits of traditional manufacturing and to help them take advantage of everything that AM, the next generation of manufacturing engineering, has to offer."
Benny Buller, founder and CEO of Velo3D, views his company's European growth as a sign of greater awareness of the production metrics delivered by advanced 3D-printing systems. "Expanding our footprint in Europe comes in response to new demand for the very highest-achievable levels of metal AM quality that only Velo3D provides--as well as design freedom that can unleash innovation and improve competitiveness for industries such as aerospace, oil and gas, and alternative energy," he says.
In March, Velo3D announced plans to merge with JAWS Spitfire Acquisition Corporation (NYSE: SPFR) and become a public company.
To learn more about how Velo3D empowers engineers and designers to imagine more and additively manufacture nearly anything, follow Velo3D on LinkedIn or visit velo3d.com.
About Velo3D
Velo3D, one of Fast Company’s 2021 World’s Most Innovative Companies , empowers engineers and designers to imagine more and additively manufacture nearly anything with a fully-integrated patented solution of software, hardware, and process-control featuring FlowTM print preparation software, AssureTM quality assurance software and the Sapphire® family of laser powder bed 3D printers. Velo3D additive manufacturing solutions for 3D-printing high-value metal parts allow for previously impossible geometries, so businesses can make the mission-critical parts they need without compromise. Customers include some of the world’s most visionary companies, such as Aerojet Rocketdyne, Chromalloy, Honeywell, LAM Research and Raytheon Technologies. For more information, follow Velo3D on LinkedIn or visit velo3d.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005582/en/
Contact information
Media Contact:
U.S.: Renette Youssef, CMO
press@velo3d.com
Europe: Jose Greses, Managing Director
jose.greses@velo3d.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
